-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 V1zoUwDvtVm3Oa92csDsshqWva/tVNMry1WQUZyyPpzjZiHXwy4T612EExVN5jfH
 OjwSJgPZBySN+xJFL0sawA==

<SEC-DOCUMENT>0000012208-07-000018.txt : 20070517
<SEC-HEADER>0000012208-07-000018.hdr.sgml : 20070517
<ACCEPTANCE-DATETIME>20070517170110
ACCESSION NUMBER:		0000012208-07-000018
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070514
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070517
DATE AS OF CHANGE:		20070517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		07861871

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k05172007.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="05/17/2007">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:691.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:13.333px; margin:0px"><BR></P>
<P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B>UNITED STATES</B></P>
<P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>Date of Report: May 14, 2007</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=719.933 colspan=3><P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B>Commission File Number: </B></P>
</TD></TR>
<TR><TD width=719.933 colspan=3><P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B><U>1-7928</U></B></P>
</TD></TR>
<TR><TD width=360><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=7.133><P style="font-size:2pt">&nbsp;</P></TD><TD width=352.8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=top width=360><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=top width=352.8><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:12px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:18.667px; margin:0px; font-size:16px" align=center><B><U>(510) 724-7000</U></B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=562.733></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=562.733><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=565.6></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=565.6><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=616.267></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=616.267><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=615></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=615><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=396.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px" align=justify><B>ITEM 1.01</B></P>
</TD><TD valign=top width=396.667><P style="margin:0px"><B>ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT</B>.</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; text-indent:32.667px">On May 14, 2007, Bio-Rad Laboratories, Inc. (the &#8220;Company&#148;) entered into a Share Purchase Agreement (the &#147;Share Purchase Agreement&#148;) with certain selling shareholders (the &#147;Sellers&#148;), pursuant to which the Company has agreed to acquire approximately 77.7% of the outstanding shares of DiaMed Holding AG (&#147;DiaMed&#148;). &nbsp;Under the terms of the Share Purchase Agreement, the Company will pay approximately 477 million Swiss francs in cash to acquire these shares from the Sellers. &nbsp;DiaMed holds approximately 9.6% of its outstanding shares as treasury shares. &nbsp;After the closing of this transaction, the Company will conduct a tender offer to acquire the remaining 12.7% of the outstanding shares of DiaMed. &nbsp;A portion of the consideration payable to the Sellers will be placed in escrow to satisfy certain contingent liabilities, including a potential payment adjustment based on DiaMed&#146;s closing financial statements,
 potential breaches or non-fulfillments of Sellers&#146; representations and warranties in the Agreement and potential liability under certain Sellers&#146; indemnities set forth in the Agreement. &nbsp;The transaction is subject to certain closing conditions, including receipt of necessary regulatory approvals and clearances.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; text-indent:32.667px">On May 16, 2007, the Company issued a press release relating to the execution of the Share Purchase Agreement. The</P>
<P style="margin:0px">&nbsp;full &nbsp;text of the press release is attached hereto as Exhibit 99.1 and is incorporated into this report as if fully set forth herein. </P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=492.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=492.667><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=24></TD><TD width=497.533></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD width=497.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px"><B>Exhibit</B></P>
<P style="margin:0px"><B>Number&nbsp;</B></P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=60><P style="margin-top:2.2px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin-top:2.2px; margin-bottom:0px">&nbsp;</P>
</TD><TD valign=bottom width=497.533><P style="margin-top:2.2px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated May 16, 2007</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on</P>
<P style="margin:0px">&nbsp;its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px">&nbsp;&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=185.667></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=189.667 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=189.667 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=219.133 colspan=3><P style="margin:0px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=189.667 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="margin:0px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="margin:0px">May 17, 2007</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="margin:0px">By:</P>
</TD><TD valign=bottom width=189.667 colspan=2><P style="margin:0px">&nbsp;<U>/s/ Christine A. Tsingos</U></P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=185.667><P style="margin:0px">Christine A. Tsingos<U> </U></P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=185.667><P style="margin:0px">Vice President,</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=185.667><P style="margin:0px">Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=34.2></TD><TD width=28.267></TD><TD width=513.533></TD></TR>
<TR><TD width=34.2><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD width=513.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=34.2><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Exhibit</B></P>
<P style="line-height:12px; margin:0px; font-size:9.333px"><B>Number</B></P>
</TD><TD valign=bottom width=28.267><P style="margin:0px; font-size:9.333px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=513.533><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=34.2><P style="margin:0px">99.1</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=513.533><P style="margin:0px">Press release of Bio-Rad Laboratories, Inc. dated May &nbsp;16, 2007</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex991051707.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Exhibit 99</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="05/17/2007">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="line-height:26.667px; margin:0px; font-family:Times New Roman Bold; font-size:16px" align=right><FONT FACE="Times New Roman Bold"><U>Exhibit 99.1</U></FONT></P>
<P style="line-height:21.733px; margin-top:6.133px; margin-bottom:6.133px; font-family:Times New Roman Bold; font-size:14.667px"><I>FOR IMMEDIATE RELEASE</I></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:26.667px; margin:0px; font-size:16px" align=center><FONT FACE="Times New Roman"><B>BIO-RAD SIGNS DEFINITIVE AGREEMENT TO ACQUIRE DIAMED &nbsp;</B></FONT></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px"><B>HERCULES, CA &#150; May 16, 2007</B> &#150; Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed a definitive agreement to acquire approximately 77.7% of the outstanding shares of DiaMed Holding AG. Under the terms of the agreement, Bio-Rad will pay approximately 477 million Swiss francs in cash to acquire these shares. DiaMed holds approximately 9.6% of its outstanding shares as treasury shares. After the closing of this transaction, Bio-Rad will conduct a tender offer to acquire the remaining 12.7% outstanding shares. The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close later this year. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<A NAME="OLE_LINK1"></A><A NAME="OLE_LINK2"></A><P style="line-height:21.333px; margin:0px; font-size:14.667px">DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening. Founded in 1977 and based in Switzerland, DiaMed has annual sales of approximately US $200 million to hospitals, clinical laboratories, and blood banks in more than 100 countries. Today, DiaMed has nearly 800 employees at various locations around the world. &nbsp;&nbsp;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">&#147;DiaMed has an outstanding reputation for quality products and customer care and we believe this portfolio of products will fit in well with Bio-Rad&#146;s existing diagnostics business,&#148; said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px"><B>About Bio-Rad</B></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www.bio-rad.com. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-size:14.667px" align=center>(more)</P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-size:14.667px; page-break-before:always">Bio-Rad Signs Definitive Agreement to Acquire DiaMed</P>
<P style="line-height:24.667px; margin:0px; padding-right:43.2px; font-size:14.667px">Page 2</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px"><B>About DiaMed</B></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">DiaMed was founded in 1977 by a small group of experts in laboratory diagnostics for the development and manufacture of test systems aimed at providing laboratories with ease of use, safety, and reliability. The DiaMed-ID Micro Typing System revolutionized work in blood group serology laboratories. Today, DiaMed is one of the leading companies in blood group serology, with over a million tests performed daily around the world with the ID-System. DiaMed has nearly 800 employees worldwide. For more information, visit www.diamed.ch.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Various statements made within this press release may constitute &#147;forward-looking statements&#148; for the purposes of the Securities and Exchange Commission&#146;s &#147;safe harbor&#148; provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company&#146;s expectation.</P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px"><B>For more information contact:</B></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Ron Hutton, Treasurer</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">+1-510-724-7000</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">investor_relations@bio-rad.com</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
